Investment Advisory, Morningside Ventures
Jason Dinges is currently an investment advisor at Morningside Technology Advisory LLC, which he joined in 2011. Dr. Dinges is also a director of several biopharmaceutical or biotechnology companies across a broad spectrum of therapeutic areas including: Kezar Life Sciences, Enyo Pharma, CellCentric, Pinteon Therapeutics, Cognito Therapeutics, Cancer Targeting Systems, Matatu, Bacainn Biotherapeutics, ClearB Therapeutics, and Alms Therapeutics. He has also facilitated multiple financings for private companies. From 2006 to 2011, Dr. Dinges was an associate attorney at Foley & Lardner LLP, practicing intellectual property law in the firm’s Chemical, Biotechnology, and Pharmaceutical practice group. Dr. Dinges received his Ph.D. in genetics from Iowa State University and a J.D., with highest distinction, from the University of Iowa College of Law.